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Background: Microvascular obstruction (MVO) describes suboptimal tissue perfusion despite restoration of
infarct-related artery flow. There are scarce data on Infarct Size (IS) and MVO in relation to the mode and timing of
reperfusion. We sought to characterise the prevalence and extent of microvascular injury and IS using Cardiovascular
magnetic resonance (CMR), in relation to the mode of reperfusion following acute ST-Elevation Myocardial Infarction
(STEMI).
Methods: CMR infarct characteristics were measured in 94 STEMI patients (age 61.0 ± 13.1 years) at 1.5 T. Seventy-three
received reperfusion therapy: primary percutaneous coronary-intervention (PPCI, n = 47); thrombolysis (n = 12);
rescue PCI (R-PCI, n = 8), late PCI (n = 6). Twenty-one patients presented late (>12 hours) and did not receive
reperfusion therapy.
Results: IS was smaller in PPCI (19.8 ± 13.2% of LV mass) and thrombolysis (15.2 ± 10.1%) groups compared to
patients in the late PCI (40.0 ± 15.6%) and R-PCI (34.2 ± 18.9%) groups, p <0.001. The prevalence of MVO was similar
across all groups and was seen at least as frequently in the non-reperfused group (15/21, [76%] v 33/59, [56%],
p = 0.21) and to a similar magnitude (1.3 (0.0-2.8) v 0.4 [0.0-2.9]% LV mass, p = 0.36) compared to patients receiving
early reperfusion therapy. In the 73 reperfused patients, time to reperfusion, ischaemia area at risk and TIMI grade
post-PCI were the strongest independent predictors of IS and MVO.
Conclusions: In patients with acute STEMI, CMR-measured MVO is not exclusive to reperfusion therapy and is
primarily related to ischaemic time. This finding has important implications for clinical trials that use CMR to
assess the efficacy of therapies to reduce reperfusion injury in STEMI.
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In the setting of acute ST-segment elevation myocardial
infarction (STEMI), microvascular obstruction (MVO)
describes suboptimal tissue perfusion despite restoration
of flow in the infarct-related artery (IRA). MVO is gen-
erally thought to be related primarily to reperfusion
injury [1-3]. Cardiovascular magnetic resonance (CMR)* Correspondence: gerry.mccann@uhl-tr.nhs.uk
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unless otherwise stated.provides unique characterisation of myocardial injury
post STEMI [4].
CMR-measured MVO correlates strongly with ST-
segment resolution in patients undergoing primary percu-
taneous coronary intervention (PPCI) but relatively weakly
with myocardial blush-grade and poorly with TIMI flow
[5]. Larger infarcts on CMR are consistently associated
with larger ventricular volumes, lower ejection fraction
and greater MVO [6], which occurs in 40-60% of patients
treated by primary percutaneous coronary intervention
(PPCI). CMR-derived infarct size (IS) [4,7] and MVO [8,9]d. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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nosis post STEMI.
The European Society of Cardiology (ESC) [10] advo-
cates four reperfusion strategies for acute STEMI: PPCI,
thrombolysis, rescue coronary angioplasty (R-PCI) and
late PCI (>12 hours after symptoms). There is a paucity
of data on the prevalence and extent of MVO following
STEMI, with different reperfusion therapies [11,12], and
in particular in patients who do not receive any reperfusion
therapy.
This study aimed to characterise the prevalence and ex-
tent of microvascular injury (MVO) and IS using CMR, in
relation to the mode of reperfusion following STEMI.Methods
Subjects and reperfusion therapy
Ninety-seven patients presenting to a single regional car-
diac centre with a first acute STEMI from Jan 2010 to April
2012 were included. Diagnosis of STEMI was made accord-
ing to ACCF/AHA and ESC definitions [10]. Seventy-six
patients who received one of the four advocated reperfusion
strategies were recruited prospectively in a study assessing
left ventricular (LV) remodeling (Figure 1). Three pa-
tients were excluded due to inability to complete CMR.
The remaining 73 patients were treated as follows: PPCI
(n = 47), thrombolysis (n = 12), R-PCI (n = 8), late PCI
(n = 6). Reperfusion therapy was decided at the point of
first medical contact according to local guidelines. Late
PCI patients underwent PCI >12 hours after symptom on-
set (TTR) in the presence of electrocardiographic or clinical
evidence of ongoing ischaemia. Twenty-one consecutive
STEMI patients who presented late (>12 hours after
symptom onset) and were symptom-free on arrival and didFigure 1 Study recruitment.not receive reperfusion therapy formed the non-reperfused
cohort. These patients underwent clinical CMR to assess
myocardial viability. The local research ethics committee
approved the study and prospectively recruited patients
provided written consent prior to participation.
‘Early-reperfused’ patients were defined as those under-
going successful initial reperfusion within 12 hours of
symptoms (PPCI, successful thrombolysis). Thrombolysis
was performed in patients presenting to non-PCI capable
regional hospitals using tissue plasminogen-activator ana-
logues. Successful thrombolysis was defined as symptom
resolution and ≥50% resolution of ST-segment elevation
within 90 minutes, and was followed by transfer to our
centre for coronary angiography. Immediate transfer for
R-PCI was undertaken for thrombolysis failure. Time to
reperfusion (TTR) was measured as the time between
symptom onset and successful restoration of IRA flow for
PCI-related revascularisation, and time until administra-
tion of successful thrombolytic therapy for thrombolysed
patients.Angiographic assessment
The Thrombolysis in Myocardial Infarction (TIMI) scoring
system was used to quantify angiographic IRA flow [13].
The degree of collateral flow to the IRA territory was
quantified using the Rentrop Score (Grade 0: absent vis-
ible collateral flow; Grade 1: IRA side-branches only filled;
Grade 2: partial filling of main IRA vessel; Grade 3: IRA
completely filled by collaterals) [14].CMR image acquisition
CMR was performed on all subjects during the index
admission on a 1.5 T scanner (Siemens Avanto, Erlangen,
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a 6-channel phased-array cardiac receiver coil supervised
by a cardiologist with a subspecialist interest in CMR
(Figure 2). Cine imaging with steady-state free preces-
sion and Late Gadolinium Enhancement (LGE) imaging
were performed in long-axis views and contiguous short-
axis slices covering the entire LV. LGE images were ac-
quired 10–15 minutes after contrast administration using
a segmented inversion-recovery gradient-echo sequence.
The inversion time was progressively adjusted to null un-
affected myocardium. T2-weighted short-tau inversion
recovery (T2w-STIR) imaging with coil signal intensity
correction was performed on the 73 prospectively recruited
reperfused subjects and not on the 21 non-reperfused
patients since they underwent a routine clinical CMR
protocol to assess for viability.CMR image analysis
Analysis was performed offline blinded to patient details
using QMass 7.1 (Medis, Leiden, Netherlands) by two
experienced observers (JNK, NAR with 3 years CMR
experience each). LV volumes and function were cal-
culated as previously described [5]. Ischaemic area at
risk ([AAR] oedema) was defined semi-automatically
as areas of hyperenhancement ≥2 standard deviations
above the signal intensity of unaffected myocardium.
Infarct zone was defined semi-automatically on LGE
imaging using the Full-Width Half-Maximum (FWHM)
technique [15]. MVO was defined as areas of hypoen-
hancement within the infarct zone and was included in
the assessed IS. AAR, IS and MVO were expressed as aFigure 2 CMR protocol. SAX = short-axis, LV = left ventricle, RV = right ven
at risk, IMH = intramyocardial haemorrhage, LGE = late gadolinium enhancepercentage of LV end-diastolic mass (%LVM) and LV
volumes were indexed by body-surface area.
Statistical analysis
Normality was assessed using the Kolmogorov-Smirnov
test, histograms and Q-Q plots. Normally distributed data
were expressed as mean ± standard deviation and analysed
using ANOVA and independent t-tests. Non-normally
distributed variables were expressed as median (25%-75%
interquartile range) and analysed using Mann–Whitney
U-tests. Chi-squared analysis was used to compare MVO
prevalence between cohorts. The association between time
from symptom onset to revascularisation (TTR), AAR, time
to CMR after admission, left anterior descending artery in-
farct related artery (LAD IRA), TIMI flow pre and post-PCI
and revascularisation method with IS and MVO were
assessed for reperfused patients using univariate regression.
Predictors with p < 0.1 underwent stepwise multivariate
analysis. Since categorical and continuous variables were
used, the strength of variables was expressed according to
their p-value. CMR markers were corrected for TTR using
ANCOVA. Reproducibility of CMR analysis was assessed
using two-way mixed-effect intraclass correlation coeffi-
cient for absolute agreement (ICC) for a subset of 10 ran-
domly chosen studies. Statistical tests were performed on
SPSS version 20. p < 0.05 was considered significant.
Results
Baseline characteristics
Baseline demographics and angiography findings are
summarised in Table 1. Diabetes was more prevalent intricle, T2w-STIR = T2-weighted short-tau inversion recovery, AAR = area
ment, MVO = microvascular obstruction.
Table 1 Baseline demographics and angiographic data by reperfusion therapy
Variable Group 1, n = 47 Group 2, n = 12 Group 3, n = 8 Group 4, n = 6 Group 5, n = 21 p
(PPCI) (Thrombolysis) (Rescue-PCI) (Late PCI) (Non-reperfused)
Age (years) 60.5 ± 12.3 59.3 ± 10.6 59.5 ± 12.5 54.7 ± 12.1 65.6 ± 16.2 0.37
Male sex (n,%) 42 (89.7) 11 (91.7) 8 (100) 5 (83.3) 16 (76.2) 0.21
Current smoking (n,%) 23 (48.9) 6 (50) 3 (37.5) 1 (16.7) 9 (42.9) 0.64
Diabetes (n,%) 2 (4.3) 1 (0) 0 (0) 0 (0) 6 (28.6) 0.01
Angina (n,%) 2 (4.3) 1 (8.3) 0 (0) 0 (0) 5 (23.8) 0.07
TTR (mins) 150 (120–240) 210 (75–300) 285 (211.25-345) 1113 (810–1342) n/a <0.001
Peak CK (iU/L) 875 (415.3-2061) 1034 (334.5-1384) 3002 (758–5045.5) 2633 (1073.3-5852) 1033 (87.8-2220.3) 0.88
Angiography (n = 15)
LAD IRA (n,%) 19 (40.4) 6 (50) 4 (50) 6 (100) 8 (53.3) 0.10
LCX IRA (n,%) 8 (17.0) 0 (0) 1 (12.5) 0 (0) 4 (26.7) 0.10
RCA IRA (n,%) 20 (42.6) 6 (50) 3 (37.5) 0 (0) 3 (20.0) 0.10
Multi-vessel disease (n,%) 16 (34) 4 (33.3) 1 (12.5) 0 (0) 5 (33.3) 0.38
Rentrop Score 0 (0–1) 0 (0–0) 0 (0–0) 0 (0-) 0 (0–0) 0.51
Rentrop B (Grd 2–3, n,%) 6 (13.3) 0 (0) 0 (0) 1 (16.7) 1 (6.7) 0.50
TIMI flow pre 0-II (n,%) 43 (95.6) 6 (83.3) 8 (100) 5 (83.3) 12 (80.0) 0.27
TIMI flow post III (n,%) 31 (68.9) 9 (58.3) 4 (50) 4 (66.7) n/a 0.82
GPIIb/IIIa inhibitor use 18 (41.9) 0 (0) 3 (37.5) 2 (40) n/a 0.39
Thrombectomy catheter? 20 (42.6) 0 (0) 5 (62.5) 1 (16.7) n/a 0.01
Angiographic data available for 88/94 patients (angiography not performed in 6/21 non-reperfused patients).
TTR = time from symptom onset to revascularisation, PPCI = primary percutaneous coronary angioplasty, IRA = infarct-related artery, LAD = left anterior descending
artery, LCX = left circumflex artery, RCA = right coronary artery, TIMI = thrombolysis in myocardial infarction, (pre) = TIMI score at start of coronary angiogram,
(post) = TIMI score post-PCI, GPIIb/IIIa = glycoprotein IIb/IIIa inhibitor.
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PCI patients than the other groups. TIMI flow grade in
successfully thrombolysed patients at the start of angiog-
raphy was higher than in the other cohorts. Fifteen (71.4%)
non-reperfused patients underwent coronary angiography
(pre-CMR in 6 patients; post-CMR in 9). In 12 (80%) of
these patients, TIMI flow-grade was abnormal (TIMI-0 in 6
patients, TIMI-1 in 4, TIMI-2 in 2).
CMR data
CMR data are shown in Table 2. The median time from
admission to CMR was longer in the non-reperfused
cohort compared with the other reperfusion strategies.
Volumes and function
LV volumes were higher and LV ejection fraction lower in
the late-PCI, R-PCI groups and non-reperfused cohorts
compared with the PPCI and thrombolysed patients. In
reperfused patients, when corrected for TTR, the differ-
ences in LVESVI and LVEF were no longer significant
(Table 2).
IS, AAR and MVO
IS differed across the five study cohorts, being higher in
R-PCI and late PCI groups compared with PPCI and
thrombolysed patients (late PCI vs PPCI p = 0.015, latePCI vs thrombolysis p = 0.008, late PCI vs non-reperfused
p = 0.014, R-PCI vs thrombolysis p = 0.06 on subgroup
analysis). When corrected for TTR, the differences in IS
in reperfused patients were no longer statistically signifi-
cant (p = 0.33).
AAR was significantly larger in the late PCI group
compared with those undergoing the 3 alternative reper-
fusion techniques (p < 0.01 compared with each strategy
on subgroup analysis). When corrected for TTR, differ-
ences in AAR were only of borderline statistical significant
(p = 0.054).
The prevalence of MVO was similar in the 5 cohorts.
There was a trend towards the extent (% of LV mass) of
MVO being greatest in the late PCI group, followed by
non-reperfused and R-PCI patients. When corrected for
TTR, the difference in MVO with the four reperfusion
techniques was not statistically significant. Representa-
tive CMR and angiography images from patients in the 5
cohorts are shown in Figure 3.
Interobserver and intraobserver agreement of CMR analysis
of infarct characteristics
Interobserver agreement for IS, MVO, AAR and MSI
was excellent, with ICCs of 0.905, 0.958, 0.888 and 0.931
respectively. Intraobserver agreement was also excellent,
with ICCs as follows: (a) observer 1: IS (0.980), MVO
Table 2 CMR data by reperfusion therapy
Variable Group 1,
n = 47 (PPCI)
Group 2, n = 12
(Thrombolysis)
Group 3, n = 8
(Rescue-PCI)
Group 4, n = 6
(Late PCI)




Time admission-CMR (d) 1.8 (1.1-2.6) 2.2 (1.3-2.6) 1.9 (1.4-3.8) 1.9 (1.5-3.6) 6.6 (4.8-11.0) <0.001 –
LVEDVI (ml/m2) 91.6 (84.9-102.7) 83.8 (76.1-107.6) 99.7 (88.5-116.6) 99.3 (83.7-106.7) 98.0 (88.1-125.0) 0.08a 0.44a
LVESVI (ml/m2) 51.3 (47.5-62.6) 55.1 (38.1-80.6) 63.1 (48.9-79.7) 64.1 (52.8-71.6) 61.1 (54.0-83.6) 0.03a 0.39a
LVMI (g/m2) 50.0 (47.4-55.7) 46.3 (42.8-67.3) 50.9 (43.2-56.7) 48.8(42.0-59.6) 58.0 (50.4-63.9) 0.24a 0.96a
LVEF (%) 42.0 ± 7.9 43.3 ± 7.5 36.5 ± 9.4 37.1 ± 10.0 35.0 ± 11.3 0.02 0.34
AAR (%LVM) 48.6 (35.9-66.5) 63.0 (49.7-65.3) 56.8 (37.6-67.7) 89.2 (77.2-98.1) n/a 0.001 0.05
IS (%LVM) 25.4 ± 16.0 20.5 ± 12.5 39.8 ± 21.8 47.4 ± 22.7 23.8 ± 11.5 0.02a 0.33a
MVO presence (%) 26 (55.3%) 7 (58.3%) 5 (62.5%) 6 (100%) 15 (71.4%) NS –
MVO (%LVM) 0.5 (0.0-3.3) 0.2 (0.0-3.9) 1.2 (0.0-4.6) 6.4 (1.0-14.8) 1.3 (0.0-2.8) 0.08 0.37
PPCI = primary percutaneous coronary angioplasty, LVEDVI = left ventricular end-diastolic volume index, LVESVI = left ventricular end-systolic volume index, LVMI = left
ventricular end-diastolic mass index, LVEF = left ventricular ejection-fraction, AAR = ischaemic area at risk (%LV mass), IS = infarct size (%LV mass), MSI =myocardial
salvage index (%), MVO=microvascular obstruction (%LV mass).
aanalysed using Log10 transformed data.
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(0.991), MVO (0.991), AAR (0.948), MSI (0.982).Predictors of IS and MVO in patients receiving
reperfusion therapy
In reperfused patients (n = 73), univariate predictors of
IS were TTR, AAR, LAD IRA, reperfusion method,
TIMI grade post-PCI and time from admission to CMR.
In a stepwise multivariate model including all of the above
plus TIMI grade pre-PCI, independent predictors of IS
were TTR, AAR and TIMI grade post-PCI (model R2 =
0.41, Table 3).Figure 3 Representative images of LGE CMR and coronary anatomy at th
images from a patient within each of the 5 study cohorts, demonstrating infarc
areas within infarct. Middle row: coronary angiography images at the start of ang
star denotes culprit lesion (right coronary artery in PPCI and lysis patient, left circ
non-reperfused patient). Bottom row: Time from symptoms to revascularisationUnivariate predictors of MVO extent were TTR, AAR,
reperfusion method and TIMI grade pre-PCI (Table 4).
In a multivariate model including TTR, AAR, reperfusion
method, TIMI-grade pre-PCI and TIMI-grade post-PCI,
independent predictors of MVO were AAR, TIMI grade
post-PCI and TTR (model R2 = 0.23, Table 4).IS and MVO in early v non-reperfused patients
The 59 patients receiving PPCI or successful lysis (<12 h)
were grouped together as the ‘early-reperfused’ group for
comparison with the non-reperfused group (n = 21) and
results are shown in Table 5. LV volumes were higher ande start of angiography in the cohorts. Top row: CMR late gadolinium
t (enhancement); microvascular obstruction (arrow) evident as hypointense
iography in the same patients demonstrating infarct related artery; white
umflex in rescue-PCI patient, left anterior descending artery in late PCI and
(TTR) and CMR data for the same patients.
Table 3 Predictors of Infarct Size (IS) in reperfused
patients
Dependent variable for IS r R2 B p
Univariate
TTR (mins)a 0.47 0.21 26.17 <0.001
AAR (%LVM) 0.46 0.20 0.39 <0.001
LAD IRA 0.39 0.15 – 0.001
Reperfusion method 0.39 0.15 – 0.003
TIMI grade post-PCI 0.32 0.09 −8.23 0.006
Time from admission to CMR (d) 0.29 0.07 4.62 0.01
TIMI grade pre-PCI 0.15 0.01 −2.74 0.22
Multivariate
(Strongest model = TTR + AAR + LAD IRA +
Reperfusion method + TIMI post + Time
from admission to CMR):
0.41
TTR (mins)a 17.72 0.02
AAR (%LVM) 0.23 0.02
TIMI grade post-PCI −5.21 0.04
LAD IRA 6.49 0.10
Time from admission to CMR (d) 2.54 0.12
Lysis v PPCI −8.60 0.08
R-PCI v PPCI 6.45 0.27
Late PCI v PPCI −7.05 0.45
PCI = percutaneous coronary intervention, TTR = time from symptom onset to
revascularisation, AAR = ischaemic area at risk (%LV mass), IRA = infarct-related
artery, LAD = left anterior descending artery, TIMI = thrombolysis in myocardial
infarction, R-PCI = rescue PCI.
aanalysed using Log10 transformed data.
Table 4 Predictors of MVO extent in reperfused patients
Dependent variable for MVO r R2 B p
Univariate
TTR (mins)a 0.37 0.13 0.27 0.001
AAR (%LVM) 0.39 0.14 0.004 0.001
Reperfusion method 0.40 0.13 – 0.008
TIMI grade pre-PCI 0.35 0.08 −0.32 0.03
TIMI grade post-PCI 0.32 0.06 −0.98 0.06
LAD IRA 0.16 0.01 – 0.18
Time from admission to CMR (d) 0.12 0.01 0.02 0.33
Multivariate
(Strongest model = TTR + AAR + TIMI post) 0.23
AAR (%LVM) 0.003 0.01
TIMI grade post-PCI −0.08 0.03
TTR (mins)a 0.16 0.049
PCI = percutaneous coronary intervention, TTR = time from symptom onset to
revascularisation, IRA = infarct-related artery, LAD = left anterior descending
artery, TIMI = thrombolysis in myocardial infarction, AAR = ischaemic area at
risk (%LV mass).
aanalysed using Log10 transformed data.







Age (y) 60.2 ± 11.9 65.6 ± 16.2 0.11
Male sex (%) 53 (89.8) 16 (76.2) 0.12
Time admission-CMR (d) 1.9 (1.2-2.6) 6.6 (4.8-11.0) <0.001
LVEDVI (ml/m2) 90.7 (82.4-102.7) 98.0 (88.1-125.0) 0.005
LVESVI (ml/m2) 51.4 (45.4-62.6) 61.1 (54.0-83.6) 0.002
EF (%) 42.3 ± 7.8 35.0 ± 11.3 0.002
IS (%LVM) 24.4 ± 15.3 23.8 ± 11.5 0.87
MVO prevalence (n,%) 33 (55.9%) 15 (71.4%) 0.21
MVO (%LVM) 0.4 (0.0-2.9) 1.3 (0.0-2.8) 0.36
PPCI = primary percutaneous coronary angioplasty, LVEDVI = left ventricular
end-diastolic volume-index, LVESVI = left ventricular end-systolic volume-index,
LVEDMI = left ventricular end-diastolic mass, LVEF = left ventricular ejection
fraction, IS = infarct size (%LV mass), MVO =microvascular obstruction
(%LV mass).
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early-reperfused group. IS was similar in the two groups
despite CMR being performed later in the non-reperfused
group. The prevalence and extent of MVO was similar in
the two groups. Representative CMR and angiographic
images from patients within our 5 study groups are shown
in Figure 3.
Discussion
Microvascular obstruction is widely regarded as a mani-
festation of reperfusion injury after STEMI [1-3,16,17].
Here, we demonstrate that MVO occurs frequently in all
forms of reperfusion therapy for STEMI, but also in those
presenting late, receiving no specific reperfusion therapy.
Although IS and the extent of MVO appeared to be great-
est in those receiving reperfusion late (R-PCI or late PCI]),
this difference was not statistically significant when ad-
justed for TTR, an important determinant of IS [18,19]
and prognosis [20] following PPCI. Indeed, there was a
similar prevalence and trend towards increased extent of
MVO in patients receiving no reperfusion therapy com-
pared with those undergoing timely reperfusion. Our find-
ings suggest that in real-life clinical patients presenting
with STEMI, CMR-measured MVO is primarily an ischae-
mic injury rather than a reperfusion injury per se. This
may have implications for currently planned and future
trials in PPCI assessing therapies specifically designed to
reduce reperfusion injury.
CMR-MVO and reperfusion injury
‘No-reflow’ was first demonstrated in canine myocardium
in 1974 [3], and is characterized by ultrastructural changes
secondary to severe microvascular injury [1,16]. MVO is
generally assumed to be primarily related to reperfusion in-
jury [1-3,16,17]. Animal studies have demonstrated infarct
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tent in the first 48 hours post reperfusion, and a corre-
sponding reduction in regional blood-flow to <45% of that
pre-ischaemia, after 2 minutes of hyperaemia [21,22].
Reperfusion has been postulated to contribute to MVO
through embolization of debris [23], release of vaso-
constrictor and inflammatory substances (e.g. serotonin,
thromboxane-B) [24] and mechanical damage to the capil-
lary bed [16].
MVO is visualised on CMR by first-pass perfusion, early
gadolinium imaging and LGE imaging as hypoenhanced
areas within infarct cores [9] and is seen in up to 60% of
PPCI patients post STEMI [25]. LGE-derived MVO (‘late
MVO’) is felt to be the most important measure of MVO
because of its strong correlation with ST-segment reso-
lution, adverse ventricular remodeling [5] and major adverse
cardiovascular events [9,26]. In both experimental models
[27] and in patients treated by PPCI there is a strong correl-
ation between MVO extent and IS on CMR [28,29].
Consistent with an extensive evidence base demonstrating
correlation between the duration of ischaemia (TTR) and
the extent of myocardial injury, our non-reperfused cohort
had larger LV volumes and lower LVEF [18,19] compared
with those promptly reperfused. CMR was performed later
in the non-reperfused group. The extent of IS and MVO
measured by CMR is known to decrease during the first
week following treatment for STEMI (IS: reduction of
~21-30% in humans [30,31]; MVO: reduction of ~48% in
humans [30], ~67% in animals [32]). It is therefore likely that
had CMR been undertaken at a similar time-point after
admission in non-reperfused and early-reperfused patients,
the extent of IS and MVO may have been significantly
greater in the non-reperfused cohort. Importantly, the
FWHM technique requires minor operator input and results
in extremely high intra- and interobserver agreement for
quantification of MVO.
Our data suggest that CMR-measured MVO should
not be used as a surrogate of subclinical angiographic
‘no-reflow’ or as a specific marker of reperfusion injury.
Reperfusion injury is one component contributing to
overall IS, [16,17] but in real-world patients presenting
typically 2–3 hours after symptom onset with STEMI,
the contribution of reperfusion to overall injury may
be impossible to assess. Our data clearly show that
CMR-measured MVO is extremely prevalent in non-
reperfused patients and like IS, is strongly related to
TTR and AAR in those receiving reperfusion therapy.
This finding casts doubt on the selection of MVO, as
opposed to IS or myocardial salvage index, as the
primary CMR-based outcome in clinical trials that spe-
cifically aim to reduce reperfusion injury. As TTR is
strongly related to IS and MVO, the potential to amelior-
ate true reperfusion injury will be greatest in those who
have less ischaemic injury at the time of P-PCI, and shortduration of symptoms, e.g. <3 hours from symptom onset
may be where the benefit of effective treatments will be
realised [20,27,28].
Myocardial and microvascular damage by revascularisation
strategy
CMR characteristics were similar with PPCI and thromb-
olysis, consistent with Bodi who demonstrated no dif-
ferences in LV volumes, LVEF, IS, MVO or myocardial
salvage index (MSI) [11]. The small number of late-PCI
and R-PCI patients make statistical comparisons difficult.
Our observations are similar to Ruiz-Nodar who demon-
strated only 9% MSI with R-PCI [33], and the MERLIN
study demonstrated similar LV function at 30 days in
R-PCI compared with conservatively treated patients
[34]. The current evidence base demonstrates a lack of
prognostic benefit with late PCI [35]. All late PCI pa-
tients in our study had LAD infarcts and tended to be
younger, factors likely to influence the clinical decision
to proceed to intervention. The LAD IRA is likely to
account for their larger AAR. The effects of R-PCI and
late PCI on reducing LV myocardial and microvascular
damage in STEMI remain unclear.
Limitations
Patients were not randomized. The non-reperfused group
were retrospectively identified and underwent CMR later
than patients receiving reperfusion, however this differ-
ence should underestimate both the prevalence and extent
of MVO in this group. The numbers of patients being
treated with late PCI and R-PCI are small and no definitive
conclusions can be drawn on the infarct characteristics.
Conclusions
CMR-derived MVO is highly prevalent in STEMI patients
not receiving reperfusion therapy. CMR measured MVO
is more closely related to ischaemic time than reperfusion
therapy in STEMI and may not be a good surrogate
marker of reperfusion injury.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
GPM, IBS and AHG conceived the idea for the study and developed the
protocol. NR and GPM recruited patients and were present at study visits.
JNK and NR performed the CMR analyses. JNK performed the angiographic
analysis. JNK and NGDM performed the statistical analysis. JNK wrote the
paper, which all authors critically reviewed for content. All authors read and
approved the final manuscript.
Funding
GPM is supported by a National Institute for Health Research (NIHR)
Postdoctoral Research Fellowship. This work is part of a project grant funded
by the British Heart Foundation with support from the NIHR Leicester
Cardiovascular Biomedical Research Unit.
Received: 27 March 2014 Accepted: 14 May 2014
Published: 27 May 2014
Khan et al. Journal of Cardiovascular Magnetic Resonance 2014, 16:38 Page 8 of 9
http://jcmr-online.com/content/16/1/38References
1. Wu KC. Cmr of microvascular obstruction and hemorrhage in myocardial
infarction. JCMR. 2012; 14:68.
2. Eeckhout E, Kern MJ. The coronary no-reflow phenomenon: a review of
mechanisms and therapies. Eur Heart J. 2001; 22:729–39.
3. Kloner RA, Ganote CE, Jennings RB. The “no-reflow” phenomenon after
temporary coronary occlusion in the dog. J Clin Invest. 1974; 54:1496–508.
4. Klem I, Shah DJ, White RD, Pennell DJ, van Rossum AC, Regenfus M,
Sechtem U, Schvartzman PR, Hunold P, Croisille P, Parker M, Judd RM,
Kim RJ. Prognostic value of routine cardiac magnetic resonance
assessment of left ventricular ejection fraction and myocardial
damage: an international, multicenter study. Circ Cardiovasc Imaging.
2011; 4:610–19.
5. Nijveldt R, Beek AM, Hirsch A, Stoel MG, Hofman MB, Umans VA, Algra PR,
Twisk JW, van Rossum AC. Functional recovery after acute myocardial
infarction: comparison between angiography, electrocardiography, and
cardiovascular magnetic resonance measures of microvascular injury.
J Am Coll Cardiol. 2008; 52:181–89.
6. Hombach V, Grebe O, Merkle N, Waldenmaier S, Höher M, Kochs M, Wöhrle J,
Kestler H. Sequelae of acute myocardial infarction regarding cardiac structure
and function and their prognostic significance as assessed by magnetic
resonance imaging. Eur Heart J. 2005; 26:549–57.
7. Wu E, Ortiz JT, Tejedor P, Lee DC, Kansal P, Carr JC, Holly TA, Klocke FJ, Bonow
RO. Infarct size by contrast enhanced cardiac magnetic resonance is a
stronger predictor of outcomes than left ventricular ejection fraction or
end-systolic volume index: prospective cohort study infarct size by contrast
enhanced cardiac magnetic resonance i. Heart. 2008; 94:730–36.
8. Klug G, Mayr A, Schenk S, Esterhammer R, Schocke M, Jaschke W, Pachinger
O, Metzler B. Prognostic value at 5 years of microvascular obstruction
after acute myocardial infarction assessed by cardiovascular magnetic
resonance. J Cardiovasc Magn Reson. 2012; 14:46.
9. de Waha S, Desch S, Eitel I, Fuernau G. Impact of early vs Late
microvascular obstruction assessed by magnetic resonance imaging on
longterm outcome after st-elevation myocardial infarction: a comparison
with traditional prognostic markers. Eur Heart J. 2010; 31:2660–68.
10. Steg PG, James SK, Atar D, Badano LP, Lundqvist CB, Borger MA, Di Mario C,
Dickstein K, Ducrocq G, Fernandez-Aviles F, Gershlick AH, Giannuzzi P, Hal-
vorsen S, Huber K, Juni P, Kastrati A, Knuuti J, Lenzen MJ, Mahaffey KW, Val-
gimigli M, Van’t Hof A, Widimsky P, Zahger D, Bax JJ, Baumgartner H, Ceconi
C, Dean V, Deaton C, Fagard R, Funck-Brentano C, et al. Esc guidelines for
the management of acute myocardial infarction in patients presenting
with st-segment elevation: the task force on the management of st-
segment elevation acute myocardial infarction of the european society
of cardiology (esc). Eur Heart J. 2012; 33(20):2569–619.
11. Bodi V, Rumiz E, Merlos P, Nunez J, Lopez-Lereu MP, Monmeneu JV, Chaus-
tre F, Moratal D, Trapero I, Blasco ML, Oltra R, Sanjuan R, Chorro FJ, Llacer A,
Sanchis J. One-week and 6-month cardiovascular magnetic resonance
outcome of the pharmacoinvasive strategy and primary angioplasty for
the reperfusion of st-segment elevation myocardial infarction. Rev Esp
Cardiol. 2011; 64:111–20.
12. Thiele H, Eitel I, Meinberg C, Desch S, Leuschner A, Pfeiffer D, Hartmann A,
Lotze U, Strauss W, Schuler G. Randomized comparison of pre-hospital-
initiated facilitated percutaneous coronary intervention versus primary
percutaneous coronary intervention in acute myocardial infarction very
early after symptom onset: the lipsia-stemi trial (leipzig immediate
preho). JACC Cardiovasc Interv. 2011; 4:605–14.
13. TIMI-Collaborators. The thrombolysis in myocardial infarction (timi) trial. Phase
i findings. Timi study group. N Engl J Med. 1985; 312:932–36.
14. Rentrop KP, Cohen M, Blanke H, Phillips RA. Changes in collateral
channel filling immediately after controlled coronary artery occlusion
by an angioplasty balloon in human subjects. J Am Coll Cardiol.
1985; 5:587–92.
15. Flett AS, Hasleton J, Cook C, Hausenloy D, Quarta G, Ariti C, Muthurangu V,
Moon JC. Evaluation of techniques for the quantification of myocardial
scar of differing etiology using cardiac magnetic resonance. JACC
Cardiovasc Imaging. 2011; 4:150–56.
16. Frohlich GM, Meier P, White SK, Yellon DM, Hausenloy DJ. Myocardial
reperfusion injury: looking beyond primary pci. Eur Heart J. 2013;
34:1714–22.
17. Yellon DM, Hausenloy DJ. Myocardial reperfusion injury. N Engl J Med.
2007; 357:1121–35.18. Francone M, Bucciarelli-Ducci C, Carbone I, Canali E, Scardala R, Calabrese F,
Sardella G, Mancone M, Catalano C, Fedele F, Passariello R, Bogaert J, Agati
L. Impact of primary coronary angioplasty delay on myocardial salvage,
infarct size, and microvascular damage in patients with st-segment
elevation myocardial infarction: insight from cardiovascular magnetic
resonance. J Am Coll Cardiol. 2009; 54:2145–53.
19. Hedström E, Engblom H, Frogner F, Åström-olsson K, Öhlin H, Jovinge S,
Arheden H. Infarct evolution in man studied in patients with first-time
coronary occlusion in comparison to different species - implications for
assessment of myocardial salvage. J Cardiovasc Magn Reson. 2009;
10:1–10.
20. Gersh BJ, Stone GW, White HD, Holmes DR Jr. Pharmacological facilitation
of primary percutaneous coronary intervention for acute myocardial
infarction: is the slope of the curve the shape of the future? JAMA. 2005;
293:979–86.
21. Rochitte CE, Lima JAC, Bluemke DA, Reeder SB, Elliot R, Furuta T, Becker LC,
Melin JA. Magnitude and time course of microvascular obstruction and
tissue injury after acute myocadial infarction. Circulation. 1998;
98:1006–14.
22. Reffelmann T, Kloner RA. Microvascular reperfusion injury: rapid
expansion of anatomic no reflow during reperfusion in the rabbit. Am J
Physiol Heart Circ Physiol. 2002; 283:H1099–107.
23. Heusch G, Kleinbongard P, Bose D, Levkau B, Haude M, Schulz R, Erbel R.
Coronary microembolization: from bedside to bench and back to
bedside. Circulation. 2009; 120:1822–36.
24. Kleinbongard P, Bose D, Baars T, Mohlenkamp S, Konorza T, Schoner S, Elter-
Schulz M, Eggebrecht H, Degen H, Haude M, Levkau B, Schulz R, Erbel R,
Heusch G. Vasoconstrictor potential of coronary aspirate from patients
undergoing stenting of saphenous vein aortocoronary bypass grafts and
its pharmacological attenuation. Circ Res. 2011; 108:344–52.
25. Bogaert J, Kalantzi M, Rademakers FE, Dymarkowski S, Janssens S.
Determinants and impact of microvascular obstruction in
successfully reperfused st-segment elevation myocardial
infarction. Assessment by magnetic resonance imaging.
Eur Radiol. 2007; 17:2572–80.
26. de Waha S, Desch S, Eitel I, Fuernau G, Lurz P, Leuschner A, Grothoff M,
Gutberlet M, Schuler G, Thiele H. Relationship and prognostic value of
microvascular obstruction and infarct size in st-elevation myocardial
infarction as visualized by magnetic resonance imaging. Clin Res Cardiol.
2012; 101(6):487–95.
27. Gerber BL, Rochitte CE, Melin JA, Mcveigh ER, Bluemke A, Wu KC, Becker
LC, Lima JAC. Microvascular obstruction and left ventricular
remodelling early after acute myocardial infarction. Circulation.
2000; 101:2734–41.
28. Amabile N, Jacquier A, Gaudart J, Sarran A, Shuaib A, Panuel M, Moulin G,
Bartoli J-m, Paganelli F. Value of a new multiparametric score for prediction
of microvascular obstruction lesions in st-segment elevation myocardial
infarction revascularized by percutaneous coronary intervention.
Arch Cardiovasc Dis. 2010; 103:512–21.
29. Ørn S, Manhenke C, Greve OJ, Larsen AI, Bonarjee VVS, Edvardsen T,
Dickstein K. Microvascular obstruction is a major determinant of
infarct healing and subsequent left ventricular remodelling following
primary percutaneous coronary intervention. Eur Heart J. 2009;
30:1978–85.
30. Mather AN, Fairbairn TA, Artis NJ, Greenwood JP. Timing of cardiovascular
mr imaging after acute myocardial infarction: effect on estimates of
infarct characteristics and prediction of late ventricular remodeling.
Radiology. 2011; 261:116–26.
31. Ibrahim T, Hackl T, Nekolla SG, Breuer M, Feldmair M, Schömig A. Acute
myocardial infarction: serial cardiac mr imaging shows a decrease in
delayed enhancement of the myocardium during the 1st week after
reperfusion. Radiology. 2010; 254:88–97.
32. Ghugre NR, Pop M, Barry J, Connelly KA, Wright GA. Quantitative magnetic
resonance imaging can distinguish remodeling mechanisms after acute
myocardial infarction based on the severity of ischemic insult. Magn
Reson Med. 2013; 70(4):1095–105.
33. Ruiz-Nodara J, Feliub E, Sánchez-Quiñonesa J, Valencia-Martína J, Garcíab M,
Pinedaa J, Martínb P, Mainara V, Bordesa P, Herasa S, Quintanillaa MA, Sogor
F. Minimum salvaged myocardium after rescue percutaneous coronary
intervention: quantification by cardiac magnetic resonance. Rev Esp
Cardiol. 2011; 64:965–71.
Khan et al. Journal of Cardiovascular Magnetic Resonance 2014, 16:38 Page 9 of 9
http://jcmr-online.com/content/16/1/3834. Sutton AG, Campbell PG, Graham R, Price DJ, Gray JC, Grech ED, Hall JA,
Harcombe AA, Wright RA, Smith RH, Murphy JJ, Shyam-Sundar A, Stewart MJ,
Davies A, Linker NJ, de Belder MA. A randomized trial of rescue angioplasty
versus a conservative approach for failed fibrinolysis in st-segment elevation
myocardial infarction: the middlesbrough early revascularization to limit
infarction (merlin) trial. J Am Coll Cardiol. 2004; 44:287–96.
35. Ioannidis JP, Katritsis DG. Percutaneous coronary intervention for late
reperfusion after myocardial infarction in stable patients. Am Heart J.
2007; 154:1065–71.
doi:10.1186/1532-429X-16-38
Cite this article as: Khan et al.: Prevalence and extent of infarct and
microvascular obstruction following different reperfusion therapies in
ST-elevation myocardial infarction. Journal of Cardiovascular Magnetic
Resonance 2014 16:38.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
